A hypercoagulable state is a condition in which your blood clots more easily or more often than it should. Sometimes called thrombophilia, it can be something you’re born with or something that develops later in life due to another medical condition, medication, or major physical change like pregnancy. Up to 900,000 people in the United States are affected by blood clots each year, and an estimated 60,000 to 100,000 of those cases are fatal, according to the CDC.
Understanding what drives this condition, and whether you might be at higher risk, can help you recognize warning signs early and make sense of what your doctor recommends.
How Blood Clots Normally Form
Your body has a carefully balanced system for stopping bleeding. When you cut yourself, proteins called clotting factors work with small blood cells called platelets to form a clot at the wound site. At the same time, natural anticoagulant proteins keep that clotting response from spreading beyond where it’s needed. Once healing is underway, other proteins dissolve the clot so blood can flow freely again.
A hypercoagulable state throws this balance off. Either your body produces too much of the proteins that build clots, too little of the proteins that prevent or dissolve them, or changes in your blood vessels and blood flow create conditions where clots form in places they shouldn’t. The 19th-century framework known as Virchow’s triad captures the three broad categories that contribute to abnormal clotting: damage to blood vessel walls, sluggish or disrupted blood flow, and changes in the blood itself that make it more prone to clotting. Most clotting events involve some combination of these three factors rather than just one.
Inherited Causes
Some people are born with genetic changes that shift their clotting system toward forming clots too readily. The most common inherited thrombophilias involve either an overactive clotting protein or a shortage of one of the body’s natural blood thinners.
Factor V Leiden is the most common inherited form. A mutation in the gene for clotting factor V makes it resistant to being switched off by one of the body’s key anticoagulant proteins. About 1 in 1,000 people in the general population develops an abnormal blood clot each year. Carrying one copy of the Factor V Leiden mutation raises that risk to 3 to 8 in 1,000 per year. Carrying two copies (one from each parent) can push the risk as high as 80 in 1,000, a dramatic increase.
Prothrombin gene mutation is the second most common inherited thrombophilia. It causes the body to produce more of the clotting protein prothrombin than normal. Between 2 and 5 percent of Americans with European ancestry carry this mutation, while it is much less common in people of African, Asian, or Native American descent.
Less common inherited conditions include deficiencies of the natural anticoagulant proteins antithrombin, protein C, or protein S. Each of these proteins plays a distinct role in keeping clot formation in check, and a shortage of any one of them can tip the balance toward excessive clotting.
Many people with inherited thrombophilia go their entire lives without a clot. The genetic change raises the baseline risk, but a clot often requires an additional trigger, like surgery, immobility, or hormonal changes.
Acquired Causes
A hypercoagulable state can also develop in response to medical conditions, lifestyle factors, or physical states that alter how your blood behaves. These acquired causes are actually more common than inherited ones.
Antiphospholipid syndrome is one of the most well-known acquired thrombophilias. It’s an autoimmune condition in which the immune system produces antibodies that interfere with normal clotting regulation. Testing for it involves checking for lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2-glycoprotein-1 antibodies, all of which are typically included in a standard thrombophilia workup.
Cancer is a significant acquired risk factor. Many cancers release substances that activate the clotting system, and cancer treatments can add to that risk. People with active cancer who develop a clot are often recommended to stay on blood thinners indefinitely.
COVID-19 drew widespread attention to infection-related clotting. The virus can damage the lining of blood vessels across multiple organs, promoting both microscopic and larger clots in arteries and veins. This connection highlighted how acute illness can temporarily push the clotting system into overdrive.
Other acquired triggers include prolonged immobility (long flights, bed rest after surgery), chronic blood disorders like sickle cell anemia, obesity, smoking, and estrogen-containing medications such as birth control pills or hormone replacement therapy.
Pregnancy and Clotting Risk
Pregnancy is a natural hypercoagulable state. Your body increases production of several clotting factors while dialing back some anticoagulant activity, an evolutionary adaptation that helps prevent excessive bleeding during childbirth. Hormonal changes also cause veins to expand and blood to flow more slowly, particularly in the legs and pelvis. This combination of altered blood composition and sluggish flow checks two of the three boxes in Virchow’s triad.
Women with underlying thrombophilia, particularly antiphospholipid syndrome, face higher risks during pregnancy. For those with antiphospholipid syndrome, treatment with blood thinners during pregnancy has been shown to improve outcomes. Women with mechanical heart valves, a history of recurrent clots while on blood thinners, or chronic clot-related lung disease are considered at especially high risk for life-threatening clotting complications during pregnancy.
Symptoms to Recognize
A hypercoagulable state itself doesn’t cause symptoms. You won’t feel anything different about your blood. The symptoms show up only when a clot actually forms, and where they appear depends on where the clot lodges.
A clot in a deep vein of the leg or arm (deep vein thrombosis) typically causes sudden or gradually worsening pain, swelling, tenderness, and warmth in the affected limb. The skin may look reddish or discolored. Symptoms usually affect one side of the body, not both.
If a clot breaks free and travels to the lungs (pulmonary embolism), symptoms shift to shortness of breath, chest pain that worsens when you breathe deeply, rapid breathing, and a fast heart rate. This is a medical emergency. Pulmonary embolism accounts for a large share of the 60,000 to 100,000 annual clot-related deaths in the U.S.
Clots can also form in less typical locations, including the veins of the abdomen or brain, particularly in people with certain thrombophilias. Unusual clot locations sometimes prompt doctors to investigate for an underlying hypercoagulable condition.
How It’s Diagnosed
Testing for a hypercoagulable state usually involves a panel of blood tests. The most commonly tested inherited conditions include deficiencies of antithrombin, protein C, and protein S, along with the Factor V Leiden and prothrombin gene mutations. The panel also typically includes tests for antiphospholipid syndrome.
Timing matters. Many of these tests can give misleading results if drawn while you’re in the middle of an acute clot, taking blood thinners, pregnant, or acutely ill. Your doctor will often wait until weeks or months after a clotting event, and sometimes until you’ve stopped anticoagulant therapy, before ordering the full workup.
Not everyone who has a clot needs thrombophilia testing. Current guidelines from the American Society of Hematology are selective about who benefits from testing, since the results don’t always change treatment decisions. Testing is most useful when the results would influence how long you stay on blood thinners or affect family planning decisions.
Treatment and Long-Term Management
The primary treatment for clots caused by a hypercoagulable state is anticoagulant therapy, commonly called blood thinners. These medications don’t dissolve existing clots but prevent new ones from forming while your body gradually breaks down the clot on its own.
How long you stay on blood thinners depends heavily on what triggered the clot. If your clot was provoked by a clear, temporary risk factor that has since resolved (like surgery or a leg cast), three months of treatment is typically enough. The risk of another clot after stopping treatment in these cases is less than 3 percent over the following year.
Unprovoked clots, those that happen without an obvious trigger, are treated differently. You’ll receive at least three to six months of anticoagulation, but the conversation about whether to continue beyond that point is more nuanced. It depends on your estimated risk of another clot, your risk of bleeding from the medication, and your personal preferences. Some people choose indefinite treatment to minimize recurrence risk, while others prefer to stop and monitor.
For people with strong, ongoing risk factors like active cancer or a high-risk thrombophilia, indefinite anticoagulation is generally recommended as long as the annual bleeding risk stays below about 2 to 3 percent. For anyone on extended therapy, that decision gets revisited at least once a year to account for changes in health, new medications, and any shifts in bleeding risk.
Beyond medication, practical measures play a role in prevention. Staying mobile during long trips, using compression stockings when recommended, maintaining a healthy weight, and being aware of the added clotting risk from hormonal medications all help reduce the chance of a first or recurrent clot, especially if you know you carry an inherited thrombophilia.